Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Dec 16:9:11.
doi: 10.1186/1472-6890-9-11.

Immunohistochemical and other prognostic factors in B cell non Hodgkin lymphoma patients, Kampala, Uganda

Lynnette K Tumwine  1 , Claudio Agostinelli, Cristina Campidelli, Emmanuel Othieno, Henry Wabinga, Simona Righi, Brunangelo Falini, Pier Paolo Piccaluga, Wilson Byarugaba, Stefano A Pileri
Affiliations

Immunohistochemical and other prognostic factors in B cell non Hodgkin lymphoma patients, Kampala, Uganda

Lynnette K Tumwine et al. BMC Clin Pathol. .

Abstract

Background: Non Hodgkin lymphomas are the most common lymphomas in Uganda. Recent studies from developed countries have shown differences in survival for the different immunophenotypes. Such studies are lacking in Africa where diagnosis is largely dependent on morphology alone. We report immunohistochemical and other prognostic factors in B cell non Hodgkin lymphoma patients in Kampala, Uganda.

Methods: Non Hodgkin lymphoma tissue blocks from the archives of the Department of Pathology, Makerere University College of Health Sciences, Kampala, Uganda, from 1991-2000, were sub typed using haematoxylin and eosin, Giemsa as well as immunohistochemistry. Using tissue micro array, 119 biopsies were subjected to: CD3, CD5, CD10, CD20, CD23, CD30, CD38, CD79a, CD138, Bcl-6, Bcl-2, IRTA-1, MUM1/IRF4, Bcl-1/cyclin D1, TdT, ALKc, and Ki-67/Mib1. Case notes were retrieved for: disease stage, chemotherapy courses received and retrospective follow up was done for survival.

Results: Non Hodgkin B cell lymphomas comprised of Burkitt lymphoma [BL] (95/119) diffuse large B cell lymphoma (19/119), mantle cell lymphoma (4/119) and precursor B lymphoblastic lymphoma (1/119). For Burkitt lymphoma, good prognosis was associated with receiving chemotherapy, female gender and CD30 positivity. Only receiving chemotherapy remained significant after Cox regression analysis. Diffuse large B cell lymphomas with activated germinal centre B cell (GCB) pattern (CD10+/-, BCL-6+/-, MUM+/-, CD138+/-) had better survival (98.4 months; 95% CI 89.5 -107.3) than the others (57.3 months; 95% CI 35.5 - 79.0) p = 0.027 (log rank test).

Conclusions: Activated GCB diffuse large B cell lymphoma had a better prognosis than the others. For Burkitt lymphoma, not receiving chemotherapy carried a poor prognosis. Availability of chemotherapy in this resource limited setting is critical for survival of lymphoma patients.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Kaplan Meier survival curve for patients with Diffuse Large B Cell Lymphoma, Kampala, Uganda.
See this image and copyright information in PMC

References

    1. Camilleri-Broet S. A uniform activated B-cell like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas:analysis of 83 cases. Blood. 2006;107:190–196. doi: 10.1182/blood-2005-03-1024. - DOI - PubMed
    1. Tumwine L. B-cell non-Hodgkin lymphomas in Uganda: an immunohistochemical appraisal on tissue microarray. Hum Pathol. 2008;39(6):817–823. doi: 10.1016/j.humpath.2007.10.025. - DOI - PubMed
    1. Rosenwald A. The use of molecular profiling to predict survival after chemotherapy for diffuse large B cell lymphoma. N Eng J Med. 2002;346(25):1937–1947. doi: 10.1056/NEJMoa012914. - DOI - PubMed
    1. Rimsza L. Gene expression predicts overall survival in paraffin embedded tissues of diffuse large B cell lymphoma. Blood. 2008;112(8):3425–3433. doi: 10.1182/blood-2008-02-137372. - DOI - PMC - PubMed
    1. Dave S. Molecular Diagnosis of Burkitt's lymphoma. N Eng J Med. 2006;354(23):2431–2442. doi: 10.1056/NEJMoa055759. - DOI - PubMed